Acetylleucine

Acetylleucine
	; (S)-(-)-N-Acetyl-leucine
Names
	IUPAC name 2-Acetamido-4-methylpentanoic acid
	Other names N-Acetylleucine; N-Acetyl-L-Leucine
Identifiers
CAS Number	Racemic: 99-15-0 ; S (-): 1188-21-2 ; R (+): 19764-30-8 ;
3D model (JSmol)	Racemic: Interactive image;
3DMet	Racemic: B00487;
Beilstein Reference	1724849 (S)-(-)
ChEBI	Racemic: CHEBI:17786 ;
ChEMBL	Racemic: ChEMBL174357 ; S (-): ChEMBL56021 ;
ChemSpider	Racemic: 1918 ; S (-): 64075 ; R (+): 1042393 ;
EC Number	Racemic: 202-734-9;
Gmelin Reference	985259 (S)-(-)
KEGG	Racemic: D07350 ;
MeSH	acetylleucine
PubChem CID	Racemic: 1995; S (-): 70912; R (+): 1241420;
UNII	Racemic: K76S41V71X ; S (-): E915HL7K2O ; R (+): 91WU82GA22 ;
	InChI InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12) Key: WXNXCEHXYPACJF-UHFFFAOYSA-N ;
	SMILES Racemic: CC(C)CC(NC(C)=O)C(O)=O;
Properties
Chemical formula	C8H15NO3
Molar mass	173.212 g·mol−1
Appearance	White crystals
Melting point	−115 to −113 °C; −175 to −172 °F; 158 to 160 K
log P	−0.265
Acidity (pKa)	3.666
Basicity (pKb)	10.331
Pharmacology
ATC code	N07CA04 (WHO)
Related compounds
Related compounds	ENU
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Acetylleucine is a modified amino acid used in the treatment of vertigo and cerebellar ataxia.

Acetylleucine is also being developed as a possible treatment for several neurological disorders by IntraBio Inc. Clinical trials with acetylleucine for the treatment of three orphan, fatal, neurodegenerative disorders are underway: Niemann-Pick disease type C, GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), and ataxia–telangiectasia. In 2020, IntraBio announced the successful multinational clinical trial results of the Niemann-Pick type C clinical trial. IntraBio is also investigating acetylleucine for the treatment of common inherited and acquired neurological diseases including Lewy body dementia, amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine Acetylleucine has received orphan drug designations from the U.S. Food & Drug Administration (FDA) and the European Commission.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.